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Abstract
The effective calcineurin inhibitor (CNI) tacrolimus (Tac) is an integral part of the standard immunosuppressive regimen after
renal transplantation (RTx). However, as a potent CNI it has nephrotoxic potential leading to impaired renal function in some
cases. Therefore, it is of high clinical impact to identify factors which can predict who is endangered to develop CNI toxicity.
We hypothesized that the Tac metabolism rate expressed as the blood concentration normalized by the dose (C/D ratio) is
such a simple predictor. Therefore, we analyzed the impact of the C/D ratio on kidney function after RTx. Renal function was
analyzed 1, 2, 3, 6, 12 and 24 months after RTx in 248 patients with an immunosuppressive regimen including basiliximab,
tacrolimus, mycophenolate mofetil and prednisolone. According to keep the approach simple, patients were split into three
C/D groups: fast, intermediate and slow metabolizers. Notably, compared with slow metabolizers fast metabolizers of Tac
showed significantly lower estimated glomerular filtration rate (eGFR) values at all the time points analyzed. Moreover, fast
metabolizers underwent more indication renal biopsies (p = 0.006) which revealed a higher incidence of CNI nephrotoxicity
(p = 0.015) and BK nephropathy (p = 0.024) in this group. We herein identified the C/D ratio as an easy calculable risk factor
for the development of CNI nephrotoxicity and BK nephropathy after RTx. We propose that the simple C/D ratio should be
taken into account early in patient’s risk management strategies.
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Introduction
The calcineurin-inhibitor (CNI) tacrolimus (Tac) is one of the
most effective immunosuppressive drugs used for renal transplan-
tation (RTx). In combination with mycophenolate mofetil,
prednisolone and daclizumab, Tac regimen showed a superior
graft function, better prevention of acute rejection and superior
graft survival after 12 months compared to cyclosporine A and
sirolimus [1].
Unfortunately, Tac has a narrow therapeutic window. It can
lead to acute as well as to chronic nephrotoxicity. Acute Tac
nephrotoxicity due to high Tac levels typically presents early after
RTx as e.g. isometric vacuolizations of tubular cells. In fact, even
as early as one month after RTx, glomerulosclerosis in renal
allografts can be associated to CNI nephrotoxicity. Typical
chronic CNI-related allograft changes include tubule-interstitial
fibrosis/tubular atrophy (IF/TA), tubular microcalcifications,
glomerulosclerosis and artheriolar hyalinosis. Acute tubular
damage can be reversed within the first three months after RTx,
however, chronic lesions observed after the third month are
usually progressive ones [2–4].
Although there seems to be a strong association between higher
CNI trough levels and nephrotoxicity [5], nephrotoxic effects of
Tac can occur even at prescribed low-level regimens (4–6 ng/mL)
[6]. In that context it is important that Tac metabolism depends
on individual factors - clinical and genetic ones. Clinical variables
like haematocrit, serum albumin, age, gender, body mass index
(BMI) or absorption have been proposed to be significant
influencing variables [7,8]. However, some are still a matter of
debate. The most relevant genes encode the cytochrome-P450
enzymes CYP3A4 and CYP3A5 leading to significant differences
in Tac pharmacodynamics [9]. However, genetic profiling of
patients is still far from been a routine test and the dosage needed
to reach target Tac level varies in patients with known CYP3A
polymorphisms over the time [10]. Of higher clinical relevance is
that physicians have to take interactions influencing Tac
metabolism into account when prescribing new drugs. In the
transplant setting interactions with other immunosuppressive
drugs, such as corticosteroids, sirolimus and everolimus are
considered in daily routine. Nevertheless, the clinical relevance
of these interactions remains widely unclear [11]. Yet another
unanswered question of interest is, if the presence of CYP3A5 in
the apical tubular plasma membrane observed in kidneys with
CNI nephrotoxicity is causally relevant or not [12,13].
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Therefore, factors which can predict patients’ risk to develop
Tac side effects or promote clinically reasonable handling of Tac
are of high interest to transplant surgeons and nephrologists.
We hypothesize that the Tac metabolism rate expressed as the
simple blood concentration normalized by the dose (C/D ratio) is
such a predictor.
Materials and Methods
Study population and clinical data
We analyzed data from 311 patients who underwent RTx
between January 2007 and March 2012. Immunosuppressive
regimen consisted of Tac (Prograf), mycophenolate mofetil
(CellCept) and prednisolone (Soludecortin H/Decortin H). An
induction therapy with basiliximab (Simulect) was given at day 0
and 4. Tac was started at a dose of 0.1 mg/kg bid with a target
trough level of 7–12 ng/mL during the first month, 6–10 ng/mL
from month 2 to 3 and 3–8 ng/mL for the following time. 1 g
mycophenolate mofetil bid was administered and adapted in case
of adverse events like leukopenia, diarrhea and infections.
Prednisolone was started with 250 mg intravenous (i.v.) before
and directly after transplantation, following 3 days of 100 mg i.v.
per day. Then prednisolone was reduced by 20 mg per day.
20 mg/day was kept until the end of the first month. Afterwards, it
was tapered. 10 mg qd was continued for the first 3 months and
tapered to a maintenance dosage of 5 mg qd after 6 months.
Recipients and donor data were collected at the time of RTx.
BMI was calculated by dividing the body weight to the square of
the height. Transplant specific characterizations as HLA MM
(human leukocyte antigen mismatches), patients in the European
Senior Program (ESP), delayed graft function (DGF, defined as
dialysis within the first week after RTx), blood type of donor and
recipient, deceased or living donor transplantations, prior RTx,
cold and warm ischemia times, cytomegalovirus (CMV) status
before transplantation (donor and recipient), CMV infections
(considered relevant $1.000 copies/ml), BK virus (BKV) infections
(considered relevant $10.000 copies/ml blood) were taken from
the patient’s files. Panel reactive antibodies (PRA) at the time of
transplantation $20% defined patients as antibody-positive.
Histologic results were obtained from indication biopsies only.
All biopsy specimens had been reviewed by one pathologist
according to the revised Banff criteria [14]. Data regarding loss of
transplant function, death of patients as wells as cause of death
were collected. All data was collected retrospectively. Data of all
patients were anonymized and de-identified prior to analysis. Our
study was approved by the local ethics committee (Ethik
Kommission der A¨rtzekammer Westfalen-Lippe und der Medizi-
nischen Fakulta¨t der Westfa¨lischen Wilhelms-Universita¨t,
No. 2014-381-f-N). Written informed consent was given by all
participants at the time of transplantation for recording their
clinical data and use in anonymized analysis.
Only patients receiving standard formulation of Tac (Prograf)
had been included and Tac had to be part of the immunosup-
pressive regimen for at least 6 months. Exclusion criteria were:
switch of the immunosuppressive therapy, age ,16 years, and
patients with an estimated glomerular filtration rate (eGFR) value
lower than 10 ml/min/1.73 m2 or complete functional loss of the
transplant were dropped out of the study. Patients were also
excluded in case of lost to follow-up.
Clinical chemistry
Whole blood was analyzed for creatinine (enzymatic assay;
Creatinine-Pap, Roche Diagnostics, Mannheim, Germany) and
Tac using the automated tacrolimus (TACR) assay (Dimension
Clinical Chemistry System, Siemens Healthcare Diagnostic
GmbH, Eschborn, Germany). Only 12-h Tac trough levels were
used for analysis. Renal function was determined by eGFR
calculation using the 4-variabel modification of diet in renal
disease (MDRD) Study at month 1, 2, 3, 6, 12 and 24 after RTx
[15].
Tac metabolism rate was determined at month 1, 3 and 6 after
RTx by dividing the drug blood trough concentration (C) to the
corresponding daily Tac dose (D).
C=Dratio (ng=mL  1=mg)
~
blood Tac trough level (ng=mL)
daily Tac dose (mg)
The mean C/D ratio of the three periods was used to identify
three groups of Tac metabolizers (fast, intermediate and slow). In
order to get reliable statistical results, groups had to encounter
similar number of patients. Intermediate metabolizers were
grouped around the mean C/D ratio value of 1.29 ng/mL*1/
mg (1.05–1.54). A C/D ratio ,1.05 ng/mL*1/mg was defined as
a fast and $1.55 ng/mL*1/mg as a slow metabolism rate.
Statistical analyses
Statistical analyses of retrospective and prospective data were
performed using SAS software, Version 9.4 for Windows and IBM
SPSS Statistics 22 for Windows (IBM Corporation, Somers, NY,
USA). Inferential statistics were intended to be exploratory (to
generate hypotheses) instead of confirmatory, and were interpreted
accordingly. Thus, p-values were interpreted in Fisher’s sense,
representing the metric weight of evidence against the respective
null hypothesis of no effect. Neither a global significance level nor
local levels were determined. P-values were considered noticeable
if ,0.05 and highly noticeable if #0.01.
All P-values are two-sided. The primary target parameter was
eGFR (ml/min/1.73 m2). Standard univariate statistical analyses
were used to describe demographic and clinical parameters.
Categorical variables are shown as absolute and relative frequen-
cies. To quantify the evidence of differences between the three
groups of Tac metabolizers (fast, intermediate and slow) Fisher’s
exact tests or Chi-square tests were used. Normal-distributed
continuous variables are shown as ‘‘mean 6 standard deviation’’.
Not normal-distributed continuous variables are reported as
‘‘median [minimum – maximum]’’. The eGFR values were
compared at each time point (1 month, 2, 3, 6, 12, 24 months)
between the three Tac groups. Due to their distributional
properties one-way ANOVAs (analysis of variances) or Kruskal-
Wallis test were applied. Further, the corresponding pairwise
comparisons were performed using T-tests or Mann-Whitney U
tests without adjusting for multiple testing.
Additionally, multivariable analyses were carried out for
longitudinal data. The aim was to identify predictor variables as
well as possibly confounders on the eGFR. To account for missing
values (treated as missing at random) and repeated outcome
values, linear mixed models were fitted. The dependent variable
was eGFR (ml/min/1.73 m2). Variable selections were performed
to detect independent variables with the strongest impact on
eGFR. Potential independent variables were: age at RTx (years),
gender of the donor (female, male) weight (kg), height (cm), living
donor (yes, no), cold ischemia time (hours), warm ischemia time
(min), time points (month 1, 2, 3, 6, 12 and 24 after
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transplantation), the Tac metabolism group (fast, intermediate and
slow) and the interaction effect (Tac metabolism group*time
point). The final linear mixed model includes the main effects age,
weight, living donor transplantation, time point, Tac metabolism
group and the interaction term (Tac metabolism group*time
point). The repeated measurements were modeled using a
compound symmetry covariance structure (CS) with patient as
subject and the time point as repeated variable.
Results
Study group
Between January 2007 and March 2012, 406 patients under-
went a renal transplantation. 311 of these patients received an
initial immunosuppressive regimen with Tac, mycophenolate
mofetil, prednisolone and basiliximab. 16 patients did not reach
the end of the first month. One of these patients died after 4 days
due to a cerebral insult, 7 patients were switched to another
immunosuppression and 8 patients showed a loss of kidney
function.
248 patients fulfilled the study criteria by remaining on Tac for
at least 6 months after RTx. The patients included were between
16 and 78 years of age (51.9614.2) and 148 (59.7%) were male.
The eGFR values were collected of 295 patients after the first and
second month, of 286 patients after month 3, 248 patients after
month 6, 229 patients after month 12 and of 161 patients 24
months after RTx.
The only relevant drugs interacting with the Tac metabolism
were corticosteroids which were used in all three groups.
Tacrolimus metabolism rate
The C/D ratio was used to define patients with different Tac
metabolism rates. A C/D ratio minimum of 0.25 and a maximum
of 3.37 ng/mL*1/mg (mean value 1.29 ng/mL*1/mg) was
identified. The 248 included patients were categorized in three
groups: fast (n = 97), intermediate (n = 78) and slow metabolizers
(n = 73). The C/D ratio values showed a symmetric distribution
(Figure 1).
Descriptive statistics
Table 1 shows the characteristics of the 248 patients who
remained on Tac for $6 months after RTx. Univariate analyses
revealed a statistically noticeable correlation of the recipient’s age
and the metabolism rate. Slow metabolizers were older than fast
(p = 0.006) and intermediate metabolizers (p,0.001). Further-
more, in a paired comparison the cohort of slow metabolizers
included fewer living donor transplantations than the fast
(p = 0.015) and intermediate metabolizers (p = 0.002).
Doses and blood concentrations
The average maintaining dose for Tac was higher in the group
of fast metabolizers after 1, 3 and 6 months than in the other two
groups (p,0.001, Table 2). The mean daily dose of fast
metabolizers was approximately twice as high as the dose of slow
metabolizers.
The Tac trough levels were analyzed at the same time points.
Statistically noticeable differences were only found 1 month and 3
months after RTx, when the mean prednisolone dose was more
than 20 and 10 mg/day, respectively (Table 2). The Tac target
trough levels were met at all time points. There were no
differences of applied prednisolone doses between the three
groups.
Renal function
The eGFR values showed a symmetric distribution, so the
assumption of an approximate normal distribution could be
justified. Consequently, a linear mixed model was fitted to adjust
for possible imbalances between the independent variables that
may have an influence on the renal function and to identify
possible predictor variables. In the final model the main effects of
metabolism group (p,0.001) and of time point (p,0.001), as well
as the interaction (p= 0.054) showed an influence on the renal
function (Table 3, linear mixed model). The model based
estimates of the pairwise differences of eGFR between the
metabolism groups were calculated for each time point. At one
month after RTx fast and intermediate metabolizers already
revealed a statistically noticeable decreased renal function
compared to slow metabolizers (Figure 2a). In the 24 months
follow-up fast metabolizers had statistically noticeable lower eGFR
values (Table 3, linear mixed model).
Interestingly, the mean C/D ratio of the 25 patients with the
worst renal outcome (who developed an eGFR value of less than
30 ml/min/1.73 m2 or even turned back to dialysis) was
1.1060.46 and of patients with biopsy proven CNI nephrotoxicity
0.9260.48 ng/mL*1/mg.
Possibly, due to a drop out of patients who switched their
immunosuppression or died, the eGFR values of all three groups
showed a highly noticeable increase in the 24 month follow-up.
The univariate changes of the eGFR values since month 1 are
shown in Figure 2b. In the linear mixed model also the main
effects age (p,0.001), weight (p,0.001) and living donor
transplantation (p = 0.067) had a potential influence on the renal
function. Despite the small p-value the effect of age was very small.
Per year of age the eGFR value was 0.3 mL/min/1.73 m2 lower.
The nominal effect of weight was also quite small. Per kg weight
the eGFR value was 0.3 mL/min/1.73 m2 smaller. The influence
of living donor transplantation indicated only a trend. In these
Figure 1. Histogram of the distribution of the Tac C/D ratio (ng/
mL*1/mg). The patients showed a symmetric distribution relating to
their C/D ratio and were categorized in three groups: slow, intermediate
and fast metabolizers. Intermediate metabolizers were grouped around
the mean C/D ratio value (1.05–1.54). Patients showing a C/D ratio ,
1.05 were defined as fast metabolizers, $1.55 as slow metabolizers.
doi:10.1371/journal.pone.0111128.g001
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patients the eGFR was 3.7 mL/min/1.73 m2 per year higher than
in patients who received a deceased donor transplant.
Post-transplantation clinical characteristics
There were no statistically noticeable differences between the
three groups concerning the number of PRA, HLA MM, DGF or
CMV infections (Table 4). In the group of fast metabolizers
noticeable more patients underwent an indication renal biopsy
(p = 0.006). Although there were no differences between histolog-
ically proven T cell-mediated rejection or antibody-mediated
rejection, in the group of fast metabolizers more cases of CNI
nephrotoxicity (p = 0.015) and BK nephropathy (p = 0.024)
occured.
From time point 1 month until month 24, 58 of 295 patients
(19.7%) were switched from Tac to another immunosuppressive
drug (sirolimus, everolimus or cyclosporin A). The main reason for
a switch was CNI nephrotoxicity (assumed or identified in kidney
biopsies). In particular, in fast metabolizers the immunosuppres-
Table 1. Patients characteristics.
fast metabolizers interm. metabolizers slow metabolizers P-value
(n =97) (n =78) (n =73)
weight (kg) 74.4615.7 76.4615.1 74.0614.8 0.562a
height (m) 1.7460.1 1.7460.1 1.7060.1 0.062a
BMI (kg/m2) 24.664.3 25.164.1 25.464.4 0.451a
age (years) 50.7614.1 48.2615.3 57.5611.3 ,0.001a
gender (m/f) 54 (56%)/43 (44%) 49 (63%)/29 (37%) 45 (62%)/28 (38%) 0.581c
living donor transpl. 25 (26%) 25 (32%) 8 (11%) 0.007c
ESP transplantations 18 (19%) 12 (15%) 19 (26%) 0.242c
AB0-incompatible transplantations 1 2 1 0.712c
cold ischemic time (h) 8.365.4 7.965.5 9.664.9 0.074a
warm ischemic time (min) 30.0 (14–50) 30.0 (18–75) 30.0 (17–60) 0.378b
number of transplatations
one 82 67 56
two 11 10 16 0.251c
three 4 1 1
donor characteristics
donor age (years) 54.0613.2 51.0617.0 54.1618.2 0.389a
donor gender (m/f) 39 (40%)/58 (60%) 39 (50%)/39 (50%) 33 (45%)/40 (55%) 0.431c
BMI, body mass index; h, hours; min, minutes; ESP, European Senior Programm; a P-value is from the one-way ANOVA; b P-value is from the Kruskal-Wallis test; c P-value
is from the Fisher’s Exact test.
doi:10.1371/journal.pone.0111128.t001
Table 2. Medication doses and blood trough concentrations.
fast metabolizers interm. metabolizers slow metabolizers P-value
(n=97) (n=78) (n=73)
tacrolimus mean trough level (ng/ml) 8.261.6 9.261.8 9.561.8 ,0.001a
after 1 month 9.463.2 10.562.7 11.063.2 0.002a
after 3 months 7.862.1 9.162.9 9.562.8 ,0.001a
after 6 months 7.262.3 7.862.4 8.062.8 0.079a
tacrolimus mean daily dose (mg) 11.0 (6.3–26.7) 7.5 (4–14) 5.5 (2.33–11.5) ,0.001b
after 1 month 14 (6–40) 10 (4–22) 8 (2–20) ,0.001b
after 3 months 10 (3.5–23) 7 (3.5–13) 4.25 (2–12) ,0.001b
after 6 months 9 (3–21) 5 (2–9.5) 3 (1.5–7.5) ,0.001b
prednisolon mean daily dose (mg) 15 (3.75–36.7) 14.17 (5–70) 13.33 (0–40) 0.06b
after 1 month 20 (15–90) 20 (15–70) 20 (0–50) 0.155b
after 3 months 13.75 (2.5–30) 12.5 (5–30) 12.5 (0–30) 0.496b
after 6 months 10 (5–30) 8.5 (5–20) 7.5 (0–20) 0.114b
aP-value is from the one-way ANOVA. b P-value is from the Kruskal-Wallis test.
doi:10.1371/journal.pone.0111128.t002
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sive regimen was significantly more often changed than in slow
metabolizers (p = 0.03; Table 5).
Eleven patients (3.7%) lost their renal function within 2 years
after RTx. Of these, more fast metabolizers returned to dialysis
treatment (trend). Moreover, chronic allograft failure and CNI
nephrotoxicity appeared only in the group of fast metabolizers to
be reasons for a loss of renal function.
Mortality rate was highest in the group of fast metabolizers
when compared between the groups (7.4% vs. 4.4% vs. 4.9%).
The leading cause of death was infection (53.3%), followed by
cardiovascular events (33.3%), with no statistical differences
between the groups (Table 5).
Discussion
Our data indicate that Tac metabolism ratio of recipients of
renal allografts influences kidney function. We identified a C/D
ratio ,1.05 corresponding to fast metabolizers of Tac to be
associated with a decreased renal function in a 24 month follow-up
after RTx when compared to higher C/D ratios. We conclude
from our data that the C/D ratio in patients receiving Tac is a
simple and inexpensive tool to identify patients at risk for the
development of CNI nephrotoxicity or BK nephropathy. More-
over, a C/D ratio ,1.05 was associated with lower renal function
and higher mortality in a 24 months follow-up in our cohort when
compared to patients with higher C/D $1.05.
Former studies revealed several clinical factors which impact on
the individual Tac metabolism rate. Patients identified as fast
metabolizers encountered noticeable more females and had
predominantly an age ,60 years and a BMI ,25 kg/m2. The
corticosteroid dose is also known to have an influence on the Tac
metabolism and is the only clinical factor which might be changed
rapidly in patients with stable immunosuppressive regimen [16].
Besides, other drugs can interfere with Tac metabolism. There-
fore, it is essential to check new drugs introduced in these patients
for Tac interactions (i.e. CYP3A inhibitors or inductors) and
perform Tac level monitoring in the follow-up. Independently
from predictable factors which can change the Tac metabolism
rate, the following ones have a relatively constant effect over the
time. Age for example. Comparing the three Tac metabolizer
groups in our study, younger patients indicated to have a faster
metabolism rate than older ones. By contrast, gender had no effect
in our cohort. This is according to observations from Gijsen et al.
who identified in pediatric heart recipients age and not sex to be
related to Tac dosing [8]. Interestingly, the authors could not find
any association between renal function and Tac trough level as
well as the genotype of CYP3A expressed. Similar results had been
published for RTx patients. Mourad et al. observed a correlation
between CYP3A genotype and Tac trough concentration (as well
as age and weight did) but failed to demonstrate an impact of Tac
level to renal function within 14 days after RTx. However, the
short follow-up and the presumably changing corticosteroid doses
in this time period, which influence Tac metabolism, are
limitations of this study [17]. Interestingly, even a 5-year follow-
up in RTx patient failed to show a correlation between CYP3A
genotype and serum creatinine limiting the clinical relevance of
this information when standard therapeutic drug monitoring is
applied [10]. However, it is out of question that genetic factors
impact on the Tac metabolism. In this regard the relevance of the
fact that fast metabolizers predominantly, but not exclusively,
express the genotype CYP3A5*1 remains unclear [18].
Therefore, we think that genetic testing of patients does not add
any relevant data to our approach and counteracts our simplifi-
cation strategy. In this context, patient’s weight was excluded from
the formula, as opposed to previous studies [7,16]. However, our
approach is supported by recently published data about pharma-
cokinetics of different intestinal and hepatic CYP3A5 genotypes
who provide evidence that body weight can be removed from the
C/D ratio formula [19]. This is supported by data from Kim et al.
who could not demonstrate a relation between weight and Tac
side effects in a 5-year follow-up of RTx patients [10]. In our
study, there was no statistically noticeable difference between the
factors weight and BMI between the three groups, which allowed
us to consider these as non-mandatory factors for inclusion in the
formula.
In our opinion, identification of fast metabolizers by simply
using the C/D ratio is relevant. Fast metabolizers with a C/D
ratio,1.05 showed lower eGFR values from the first until the 24th
month after RTx than intermediate or slow metabolizers. Patients
of this group underwent frequently more indication renal biopsies
which revealed more often cases of CNI nephrotoxicity despite
lower Tac levels (Table 2). In fact, the mean C/D ratio of patients
with biopsy proven CNI nephrotoxicity in our study was ,1.05. It
Figure 2. eGFR value comparison between the three metabo-
lism groups (a). Fast and intermediate Tac metabolizers showed
statistically noticeable lower eGFR values compared to slow metabo-
lizers one month after RTx. P-values refer to the linear mixed model.
Renal function in a 24 months follow-up (b). The differences between
the follow-up eGFR values (month 2, 3, 6, 12, 24) and the eGFR value
and the eGFR value at month 1 are shown for every metabolism group.
doi:10.1371/journal.pone.0111128.g002
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would have been interesting to know, if on the other hand a C/D
ratio of ,1.05 protects from acute rejection. However, due to the
small number of acute rejections we cannot sufficiently comment
on a relation between C/D ratio and rejection. As expected
patients with a C/D ratio ,1.05 needed higher daily Tac doses
than the patients of the other two groups. The ELITE-Symphony
study supports our data by showing lower GFR values in the group
of patients receiving a higher CNI dose [1]. Kuypers et al.
identified an association between a high daily Tac dosage and
histologically proven CNI nephrotoxicity [18]. Taking the
available data into account, high daily Tac doses (in relation to
the serum level) applied in fast metabolizers may account for lower
renal function after RTx.
Furthermore, histologically proven BK nephropathy more often
occurred in fast metabolizers than in the intermediate or slow
metabolizers. Immunosuppressive regimens including Tac and
MMF are associated with an increased risk of reactivation of BKV
and BK nephropathy [20]. Borni-Duval et al. identified Tac
trough levels of more than 10 ng/mL as a risk factor for BK
nephropathy [21]. Taking together, it remains of interest and
should be addressed in further studies, if the C/D ratio could be a
more accurate predictor of BK nephropathy or not. The fact that
CNI nephropathy and BK nephropathy as well as a higher
incidence of death due to infection is related to lower C/D ratios
led us to the hypothesis that fast metabolizers might suffer from
overexposure and related over immunosuppression or toxicity at
least at some time of the day. This should be addressed in further
studies. It was questioned if Tac absorption might influence the
Tac metabolism. Enteric Tac absorption has been characterized
and factors like gastric emptying rate have been investigated.
These processes can influence early peak level but seem not to
affect trough level to a relevant extent [22–24].
Table 3. Renal function (linear mixed model).
Model-based estimates
mean eGFR lower 95% confidence limit upper 95% confidence limit P-value
living donors (yes vs. no) 3.7 20.3 7.6 0.068
weight (per kg) 20.3 20.3 20.1 ,0.0001
age at TX (per year) 20.3 20.4 20.2 ,0.0001
tacrolimus metabolism group ,0.0001
time points ,0.0001
tacrolimus metabolism groups*time points 0.054
Combinded estimates of main effects and interaction term of tacrolimus metabolism group and time points
at 1 month
intermediate vs. slow 26.2 211.6 20.8 0.026
fast vs. slow 29.0 214.1 23.9 0.0005
fast vs. intermediate 22.9 27.8 2.1 0.26
at 2 months
intermediate vs. slow 26.9 212.4 21.4 0.014
fast vs. slow 211.1 216.3 26.0 ,0.0001
fast vs. intermediate 24.3 29.3 0.7 0.096
at 3 months
intermediate vs. slow 26.9 212.5 21.3 0.015
fast vs. slow 210.9 216.1 25.7 ,0.0001
fast vs. intermediate 24.0 29.1 1.0 0.118
at 6 months
intermediate vs. slow 1.2 24.2 6.6 0.656
fast vs. slow 29.0 214.1 23.9 0.0005
fast vs. intermediate 210.2 215.2 25.3 ,0.0001
at 12 months
intermediate vs. slow 20.5 26.0 5.0 0.861
fast vs. slow 27.6 212.8 22.4 0.0043
fast vs. intermediate 27.1 212.1 22.1 0.0053
at 24 months
intermediate vs. slow 21.8 28.2 4.5 0.566
fast vs. slow 28.8 214.7 22.8 0.0039
fast vs. intermediate 26.9 212.5 21.3 0.016
Results of the final linear mixed model after variable selection. The parameter estimates for fixed effects of eGFR (ml/min/1.73 m2) are shown. P-values are from the
Wald tests. Repeated measurements were modeled using a compound symmetry covariance structure (CS) with patient as subject and the time point as repeated
variable.
doi:10.1371/journal.pone.0111128.t003
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Table 4. Antibodies, HLA MM, DGF, infections and biopsy results.
fast metabolizers interm. metabolizers slow metabolizers P-value
(n=122) (n =91) (n=82)
PRA (.20%) 2 (2%) 3 (3%) 2 (2%) –
HLA MM
no HLA MM 15 (12%) 13 (14%) 10 (12%)
1–3 HLA MM 67 (55%) 45 (50%) 50 (61%) 0.651
4–6 HLA MM 40 (33%) 33 (36%) 22 (27%)
DGF 25 (21%) 15 (17%) 11 (13%) 0.434
CMV
CMV high risk 30 (25%) 16 (18%) 20 (24%)
CMV interm. risk 77 (63%) 61 (69%) 51 (62%) 0.784
CMV low risk 15 (12%) 12 (13%) 11 (13%)
CMV infection 15 (12%) 11 (12%) 5 (6%) 0.292
BK viremia 8 (7%) 7 (8%) 1 (1%) 0.11
biopsy results
indication biopsies 53 (43%) 30 (33%) 18 (22%) 0.006
TMR 2 (2%) 4 (4%) 1 (1%) –
AMR 5 (4%) 3 (3%) 0 –
CNI-nephrotoxicity 13 (11%) 2 (2%) 2 (2%) 0.015
BK nephropathy 5 (4%) 0 0 0.024
others 28 (23%) 21 (23%) 15 (18%) –
PRA, panel reactive antibodies; HLA MM, human leucocyte antigen mismatch; DGF, delayed graft function; CMV, cytomegalovirus; TMR, T cell-mediated rejection; AMR,
antibody-mediated rejection; IF/TA, interstitial fibrosis/tubular atrophy; P-values are from the Fisher’s Exact tests; due to small frequencies some P-values are not
reported.
doi:10.1371/journal.pone.0111128.t004
Table 5. Reasons for switching immunosuppression and adverse events.
fast metabolizers interm. metabolizers slow metabolizers P-value
(n=122) (n=91) (n=82)
switch of IS 28 (23%) 16 (18%) 14 (17%) 0.523
assumed and proven CNI-tox 11 (9%) 4 (4%) 1 (1%) 0.047
adverse events 8 (7%) 5 (6%) 4 (5%) 0.948
acute rejections 1 (1%) 0 0 –
chronic allograft failure 2 (2%) 1 (1%) 0 –
infections 5 (4%) 2 (2%) 5 (5%) –
maligne diseases 0 3 (3.3%) 1 (1.2%) –
compliance 1 (1%) 1 (1%) 3 (4%) –
loss of funcion 6 (5%) 2 (2%) 3 (4%) 0.636
chronic allograft failure 2 (2%) 0 0 –
acute rejections 2 (2%) 1 (1%) 2 (2%) –
primary non-function 1 (1%) 1 (1%) 1 (1%) –
CNI nephrotoxicity 1 (1%) 0 0 –
death 9 (7%) 4 (4%) 4 (5%) 0.665
infections 6 (5%) 2 (2%) 0 0.111
maligne diseases 1 (1%) 0 1 (1%) –
bleeding 0 1 (1%) 1 (1%) –
cardiovascular 2 (2%) 1 (1%) 2 (2%) –
CNI, calcineurin inhibitor; IS, immunosuppression; P-values are from the Fisher’s Exact test; due to small frequencies some P-values are not reported.
doi:10.1371/journal.pone.0111128.t005
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During the follow-up of 24 months after transplantation a
slightly increasing mean-eGFR value was calculated in all three
groups. The most likely explanation is the drop-out of patients due
to a switch of the immunosuppression or death.
Compared to other studies, there was only a low rate of serious
events, such as loss of renal function (3.4%) and death (5.8%) in a
follow-up of 24 months [25]. By trend, in the group of fast
metabolizers, more patients died of infections than of other
reasons.
The mainly retrospective analysis of this study leads to a few
limitations. The study population was Caucasian. Therefore, the
study data is only reliable for this ethnical group with similar
genetic characteristics. According to the standard procedure of our
hospital this study contains indication renal biopsies only. Thus,
graft changes which have not been translated into significant
eGFR decreases yet could have been missed and due to the small
rejection rate, we cannot comment on the influence of C/D ratio
on rejection.To sum up, we demonstrated that Tac metabolism
rate defined by C/D ratio influences renal function within a 24
months follow-up after RTx whereas fast metabolism was
associated with a lower eGFR. If the discrimination between
intermediate and slow metabolizers will impact on therapy and
outcome should be evaluated in the future. Furthermore, we
generated hypotheses and randomized, multicenter studies should
follow to confirm these results and answer the question among
others if fast Tac metabolizers show a greater profit from a switch
to a mammalian target of rapamycin inhibitor than intermediate
or slow metabolizers.
We conclude that in order to achieve long term survival of
patients and their renal transplant it is important to minimize risk
factors potentially affecting graft survival and patient’s safety. One
central factor to succeed is an tailored immunosuppressive
regimen taking the patient’s individual situation into account.
However, in our experience only simple and cost effective
approaches have a real chance to be adopted for daily routine
by clinicians. If the proposed C/D ratio is able to fulfil these
criteria and needs, it should to be evaluated in further prospective
studies.
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